|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
9 months to Mar 31, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Excise taxes | |||||
| Net revenue | |||||
| Cost of sales | |||||
| Gross profit before fair value adjustments | |||||
| Changes in fair value of inventory sold | |||||
| Loss on changes in fair value of inventory and biological assets sold | |||||
| Gain on changes in fair value of biological assets | |||||
| Gross profit (loss) | |||||
| Operating expenses | |||||
| General and administration | |||||
| Sales and marketing | |||||
| Business development costs | |||||
| Research and development | |||||
| Depreciation and amortization | |||||
| Share-based compensation | |||||
| Operating expenses | |||||
| Income (loss) from operations | |||||
| Other income (expenses) | |||||
| Legal settlement and contract termination fees | |||||
| Interest and other income | |||||
| Finance and other costs | |||||
| Foreign exchange gain (loss) | |||||
| Other gains (losses) | |||||
| Restructuring charges | |||||
| Impairment of property, plant and equipment | |||||
| Impairment of investment in associates | |||||
| Impairment of intangible assets and goodwill | |||||
| Other income (expenses) | |||||
| Income (loss) before income tax recovery (expense) | |||||
| Income tax recovery (expense) | |||||
| Current | |||||
| Deferred, net | |||||
| Income tax recovery (expense) | |||||
| Net income (loss) from continuing operations | |||||
| Net loss from discontinued operations, net of tax | |||||
| Net income (loss) | |||||
| Other comprehensive income (loss) (“OCI”) that will not be reclassified to net income (loss) | |||||
| Other comprehensive income (loss) that may be reclassified to net income (loss) | |||||
| Realized gain on marketable securities | |||||
| Foreign currency translation gain (loss) | |||||
| Total other comprehensive income (loss) | |||||
| Comprehensive income (loss) from continuing operations | |||||
| Comprehensive income (loss) from discontinued operations | |||||
| Comprehensive income (loss) | |||||
| Net income (loss) from continuing operations attributable to: | |||||
| Aurora Cannabis Inc. | |||||
| Non-controlling interests | |||||
| Net income (loss) from discontinued operations attributable to: | |||||
| Aurora Cannabis Inc. | |||||
| Non-controlling interests | |||||
| Comprehensive income (loss) attributable to: | |||||
| Aurora Cannabis Inc. | |||||
| Non-controlling interests | |||||
| Net income (loss) per share - basic | |||||
| Basic, continuing operations (in CAD per share) | |||||
| Basic, discontinued operations (in CAD per share) | |||||
| Basic income (loss) per share (in CAD per share) | |||||
| Net income (loss) per share - Diluted | |||||
| Diluted, continuing operations (in CAD per share) | |||||
| Diluted, discontinued operations (in CAD per share) | |||||
| Diluted income (loss) per share (in CAD per share) | |||||
Loading...